MedTrace Logo

Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence

NCT05856409 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-08-16

No results posted yet for this study

Summary

This is a prospective study to investigate the potential efficacy of 68Ga-FAPI PET/CT for recurrence detection of epithelial ovarian cancer in comparison with 18F-FDG PET/CT.

Conditions

  • 68Ga-FAPI
  • Ovarian Cancer
  • Epithelial Ovarian Cancer
  • Positron Emission Tomography

Interventions

DIAGNOSTIC_TEST

68Ga-FAPI

\[68Ga\]-FAPI is tumor imaging agent for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF)

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jianjun Liu, PH.D · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2024-04-01
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05856409 on ClinicalTrials.gov